Nautilus Biotechnology

Nautilus Biotechnology is a company that aims to revolutionize the field of proteomics and fulfill the promise of the human proteome. Founded in 2016, Nautilus has made significant strides in addressing the challenges of bringing true proteomics to the world and accelerating therapeutic development, improving medical diagnostics, and making personalized and predictive medicine a reality. The team at Nautilus is comprised of experts from diverse disciplines such as protein chemistry, chip design, molecular biology, data science, material science, biophysics, optical engineering, microfluidics, bioinformatics, and software engineering, positioning the company to make significant advancements in the field of proteomics. The company has garnered significant investor interest, with a substantial $200.00M Post-IPO Equity investment on 10 June 2021 from renowned firms including Madrona, Casdin Capital, RA Capital Management, Andreessen Horowitz (a16z), Franklin Templeton, OrbiMed, Vulcan Capital, Ally Bridge Group, Perceptive Advisors, and Alyeska Investment Group. Operating at the intersection of biotechnology, healthcare, and the pharmaceutical industry, Nautilus Biotechnology is poised to significantly impact the way drugs are developed and improve human health management on a global scale. The company's headquarters is located in the United States, reflecting its position in the heart of biotechnology and healthcare innovation.